Winslow Asset Management Inc. lowered its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,286 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Winslow Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $462,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Jolley Asset Management LLC increased its position in Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 80 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol-Myers Squibb during the second quarter valued at $163,000. Solaris Asset Management LLC increased its position in Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 75 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in Bristol-Myers Squibb by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,353 shares of the biopharmaceutical company’s stock valued at $173,000 after buying an additional 12 shares during the period. Finally, Madrona Financial Services LLC bought a new position in Bristol-Myers Squibb during the second quarter valued at $200,000. Institutional investors own 72.91% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) opened at 55.43 on Friday. Bristol-Myers Squibb Co. has a 52 week low of $53.56 and a 52 week high of $77.12. The company has a 50-day moving average price of $56.41 and a 200 day moving average price of $66.79. The company has a market cap of $92.62 billion, a PE ratio of 32.42 and a beta of 0.74.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. The firm had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. Bristol-Myers Squibb’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company posted $0.53 EPS. On average, equities research analysts forecast that Bristol-Myers Squibb Co. will post $2.63 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be paid a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 87.36%.
Several research firms recently weighed in on BMY. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “buy” rating and set a $78.73 target price on the stock in a research report on Monday, July 25th. Deutsche Bank AG reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, June 15th. BMO Capital Markets reiterated a “market perform” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Saturday, September 3rd. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Finally, Leerink Swann reissued a “buy” rating and set a $69.00 price target on shares of Bristol-Myers Squibb in a report on Sunday. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $69.61.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $59.17, for a total value of $1,372,744.00. Following the transaction, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $21,596,990.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.